New obesity and metabolic syndrome treatment: The rimonabant;Nouveau traitement de l'obésité et du syndrome métabolique: Le rimonabant

Revue Medicale Suisse

Volumn 2, Issue 47, 2006, Pages 41-45

  Makoundou, Vincent ^a   Golay, Alain ^a  

^a Département de Médecine Communautaire   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; RIMONABANT; CANNABINOID RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANXIETY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; METABOLIC SYNDROME X; NAUSEA; OBESITY; REVIEW; SIDE EFFECT; VERTIGO; WEIGHT REDUCTION; EATING; INSULIN RESISTANCE; LIPID METABOLISM; PHYSIOLOGY;

EATING; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 33644853601     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Fliers JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004;116:337-50.
2. Despres JP. Health consequences of visceral obesity. Ann Med 2001;33:534-41.
3. Pasquali R, Vicennati V, Pagotto U. Endocrine determinants of fat distribution. In: Bray GA, Bouchard C, eds. Handbook of Obesity. New York: Marcel Dekker Inc, 2003;671-92.
4. Golay A, Fossati M, Delétraz M, et al. Multidisciplinary approach to obesity treatment. Diabetes, obesity and Metabolism 2003;5:274-9.
5. Abel EL. Cannabis: Effects on hunger and thirst. Behav Biol 1975;15:255-81.
6. Siler JF, Sheep WL, Bates LB, et al. Marihuana smoking in Panama. Mil Surg 1933;73:269-80.
7. Tart CT. Marijuana intoxication common experiences. Nature 1970;226:701-4.
8. Haines L, Green W. Marijuana use patterns. Br J Addict Alcohol Others Drugs 1970;65:347-62.
9. Gaoni Y, Mechoulan R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
10. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNSA. Nature 1990;346:561-4.
11. Munro S, Thomas KL, Abu-Shaar M, et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
12. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
13. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
14. Pagotto U, Vincennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005;37:270-5.
15. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience 2005;8:585-9.
16. Van Gaal L, Rissanen A, Scheen A, et al (for the RIO-Europe Study Group). Effects of the cannabinoid-1 receptor blocker Rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
17. Desprès JP, Golay A, Sjöström L, et al. Effect of Rimonabant on body weight and the metabolic syndrome in overweight patients. RIO-lipids study group. N Engl J Med 2005, in press.
18. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.
19. Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention of Diabetes in Obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
20. Yusuf S, Hawken S, Ôunpuu E, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.